瑞银发表研究报告指，泰格医药(03347.HK) 次季收入按年跌0.7%至16.9亿元人民币(下同)，跌幅较首季跌5.8%有所改窄，惟逊于该行及市场预期；净利润按年降15.5%至2.18亿元，相对首季按年跌幅为29.6%，同样逊于该行及市场预期。该行表示，泰格医药维持其全年指引，预计收入将按年增长高个位数，同时期望毛利率可按季回升，经常性净利润率有望改善。考虑到首季新订单增长，公司将全年相关预测...
Source Link瑞银发表研究报告指，泰格医药(03347.HK) 次季收入按年跌0.7%至16.9亿元人民币(下同)，跌幅较首季跌5.8%有所改窄，惟逊于该行及市场预期；净利润按年降15.5%至2.18亿元，相对首季按年跌幅为29.6%，同样逊于该行及市场预期。该行表示，泰格医药维持其全年指引，预计收入将按年增长高个位数，同时期望毛利率可按季回升，经常性净利润率有望改善。考虑到首季新订单增长，公司将全年相关预测...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.